No abstract

Current catheter devices in minimally invasive surgery still possess limited functional options, lacking multimodal integration of both sensing and therapy. Catheter devices usually operate outside the tissue, incapable to detect intra‐tissue biochemical information for accurate localization and assessment of lesions during surgery. Inspired by the feature and functions of Petromyzontidae, here a multimodal core‐shell microneedles‐integrated bioelectronic catheter (MNIBC) for tissue‐penetrating theranostics in endoscopic surgery is developed. The microneedle (MN) device possesses individually addressable functionality at single‐MN tip resolution, enabling multiplex functions (a total of 11 functions distributed in three types of catheters) including biochemical sensing, myoelectric modulation, electroporation, and drug delivery in a submucosal environment. The MNIBC is prepared through hybrid fabrication and dimensionality reduction strategies, where the MN electrodes are functionalized with an MXene‐carbon nanotube (MXene‐CNT)‐based electron mediator, addressing the challenge of reduced electrode sensitivity on ultra‐small MN tip. The functionalities of MNIBC are demonstrated both ex vivo and in vivo on anesthetized rabbits via laparoscopy, simulated cystoscopy, and laparotomy. The MNIBC can effectively detect intra‐tissue biochemical signals in the bladder, and offers localized electroporation and intra‐tissue drug delivery for precise treatments of lesions. The versatile features of the MNIBC present a highly advanced platform for precise surgeries.

Background. This study sought to perform a survival analysis and construct a prognostic nomogram model based on the Gleason grade, total prostate-specific antigen (tPSA), alkaline phosphate (ALP), and TNM stage in patients with prostate cancer (PCa). Methods. The progression-free survival (PFS) of 255 PCa patients was analyzed in this study. The prognostic value of tPSA and ALP was evaluated using the Kaplan-Meier survival curves and Cox regression analysis, and a nomogram model based on the Gleason grade, tPSA, ALP, and TNM stage was further established for PFS prediction in PCa patients. Results. PCa patients with different Gleason grades, tPSA and ALP levels, and TNM stages presented distinct PFS. The Gleason grade, tPSA, ALP, and TNM stage were four independent prognostic indicators. The C-index of the established nomogram was 0.705 for PFS in the test cohort and 0.687 for the validation cohort, and the calibration curves indicated a good consistency between predicted and actual PFS in PCa patients. Conclusion. The data of this study demonstrated that the Gleason grade, tPSA, ALP, and TNM stage of PCa patients are independently correlated with PFS, and a nomogram model based on these indicators may be valuable for the PFS prediction in PCa patient.

Introduction Hypertension and lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) are often coexist in elderly men. Men with bothersome LUTS present with various other conditions, including hypertension, heart disease and the metabolic syndrome. Severe LUTS are likely to constitute a risk factor for the development of hypertension. α (1)-blockers initially introduced for the management of hypertension and have become a standard medical therapy for LUTS. This study was conducted to describe the effect of 2 mg terazosin on LUTS in patients with concomitant mild hypertension. Objectives To investigate the therapeutic effi cacy of terazosin for mild hypertension patients with LUTS. Methods A total of 60 patients with stage 1 hypertension with LUTS (International Prostate Symptom Score-IPSS >7) at the time of fi rst examination were enrolled in this trial. They were assessed based on IPSS and IPSS-quality of life for LUTS and measurement of blood pressure (BP) for stage 1 hypertension after excluding those with normotensive and stage 2-3 hypertension. They were treated with 2 mg of terazosin once daily for 12 weeks. Changes in blood pressure and IPSS were evaluated before and after 12 weeks of the medication of terazosin. Results After 12 weeks of treatment, terazosin demonstrated effi cacy in lowering the score for IPSS and relieving LUTS. Of them, systolic and diastolic blood pressure of 51 patients (81.6%) decreased to normal. No orthostatic hypotension and other blood pressure-related adverse effects occurred in all patients.Conclusion Terazosin therapy appears to be effi cacious in relieving LUTS and decreasing blood pressure for mild hypertension patients with LUTS secondary to BPH. on 26 April 2019 by guest. Protected by copyright.